One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Validation of IBD-associated Whole-blood DNA Methylation Changes–Where Do We Go From Here?
Alexander D B Ross, Matthias Zilbauer
doi : 10.1093/ecco-jcc/jjac163
Journal of Crohn's and Colitis, Volume 17, Issue 2, February 2023, Pages 151–152,
ECCO Topical Review: Roadmap to Optimal Peri-Operative Care in IBD
Shaji Sebastian, Jonathan P Segal, Charlotte Hedin, Gianluca Pellino, Paulo Gustavo Kotze, Michel Adamina, Marjo Campmans-Kuijpers, Justin Davies, Annemarie C de Vries, Ana Gutiérrez Casbas, Alaa El-Hussuna, Pascal Juillerat, Susanna Meade, Monica Millán, Antonino Spinelli
doi : 10.1093/ecco-jcc/jjac129
Journal of Crohn's and Colitis, Volume 17, Issue 2, February 2023, Pages 153–169
Despite the advances in medical therapies, a significant proportion of patients with inflammatory bowel diseases [IBD] require surgical intervention. This Topical Review aims to offer expert consensus practice recommendations for peri-operative care to optimize outcomes of IBD patients who undergo surgery.
Analysis of Systemic Epigenetic Alterations in Inflammatory Bowel Disease: Defining Geographical, Genetic and Immune-Inflammatory influences on the Circulating Methylome
Rahul Kalla, Alex T Adams, Jan K Nowak, Daniel Bergemalm, Simen Vatn, Nicholas T Ventham, Nicholas A Kennedy, Petr Ricanek, Jonas Lindstrom, IBD-Character Consortium , Johan Söderholm, Marie Pierik, Mauro D’Amato, Fernando Gomollón, Christine Olbjørn, Rebecca Richmond, Caroline Relton, Jørgen Jahnsen, Morten H Vatn, Jonas Halfvarson, Jack Satsangi
doi : 10.1093/ecco-jcc/jjac127
Journal of Crohn's and Colitis, Volume 17, Issue 2, February 2023, Pages 170–184
Epigenetic alterations may provide valuable insights into gene–environment interactions in the pathogenesis of inflammatory bowel disease [IBD].
Systematic Review and Meta-analysis of Peripheral Blood DNA Methylation Studies in Inflammatory Bowel Disease
Vincent Joustra, Ishtu L Hageman, Jack Satsangi, Alex Adams, Nicholas T Ventham, Wouter J de Jonge, Peter Henneman, Geert R D’Haens, Andrew Y F Li Yim
doi : 10.1093/ecco-jcc/jjac119
Journal of Crohn's and Colitis, Volume 17, Issue 2, February 2023, Pages 185–198
Opportunistic Infections in Patients with Inflammatory Bowel Disease Treated with Advanced Therapies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Pablo A Olivera, Juan S Lasa, Ignacio Zubiaurre, Vipul Jairath, Maria T Abreu, David T Rubin, Walter Reinisch, Fernando Magro, Jean-François Rahier, Silvio Danese, Christian Rabaud, Laurent Peyrin-Biroulet
doi : 10.1093/ecco-jcc/jjac133
Journal of Crohn's and Colitis, Volume 17, Issue 2, February 2023, Pages 199–210
Advanced therapies for inflammatory bowel disease [IBD] could potentially lead to a state of immunosuppression with an increased risk of opportunistic infections [OIs].
Corticosteroid-Sparing Effects of Filgotinib in Moderately to Severely Active Ulcerative Colitis: Data from the Phase 2b/3 SELECTION Study
Edward V Loftus, Jr, Séverine Vermeire, Brian G Feagan, Franck-Olivier Le Brun, Alessandra Oortwijn, Ulrik Moerch, William J Sandborn, Toshifumi Hibi
doi : 10.1093/ecco-jcc/jjac122
Journal of Crohn's and Colitis, Volume 17, Issue 2, February 2023, Pages 211–220
Corticosteroid-free remission is an important treatment goal for patients with ulcerative colitis [UC]. The corticosteroid-sparing effects of filgotinib, an oral, Janus kinase 1 preferential inhibitor, were assessed in SELECTION, a placebo-controlled, phase 2b/3 trial in moderately to severely active UC.
Prophylactic Medication for the Prevention of Endoscopic Recurrence in Crohn’s Disease: a Prospective Study Based on Clinical Risk Stratification
Jeanine H C Arkenbosch, Evelien M J Beelen, Gerard Dijkstra, Mariëlle Romberg-Camps, Marjolijn Duijvestein, Frank Hoentjen, Sander van der Marel, P W Jeroen Maljaars, Sita Jansen, Nanne K H de Boer, Rachel L West, Carmen S Horjus, Laurents P S Stassen, Fiona D M van Schaik, Oddeke van Ruler, Bindia J H Jharap, Marijn Visschedijk, Alfred Janssen, Nicole S Erler, Michail Doukas, Ariadne H A G Ooms, Gursah Kats-Ugurlu, Christien Janneke van der Woude, Annemarie C de Vries On behalf of the Dutch Initiative on Crohn’s and Colitis (ICC)
doi : 10.1093/ecco-jcc/jjac128
Journal of Crohn's and Colitis, Volume 17, Issue 2, February 2023, Pages 221–230
To prevent recurrence after ileocolonic resection [ICR] in Crohn’s disease [CD], postoperative prophylaxis based on risk stratification is recommended in international guidelines.
Patients with Inflammatory Bowel Disease Have Heterogeneous Treatment Preferences That Are Largely Determined by the Avoidance of Abdominal Pain and Side Effects [P-POWER IBD Study]
Edouard Louis, Corey A Siegel, Barbara James, Sebastian Heidenreich, Nicolas Krucien, Subrata Ghosh
doi : 10.1093/ecco-jcc/jjac130
Journal of Crohn's and Colitis, Volume 17, Issue 2, February 2023, Pages 231–239
Patient-centric management of inflammatory bowel disease [IBD] is important, with consensus considering patient-reported outcomes alongside clinical and endoscopic assessment by healthcare providers.
Incidence, Prevalence, Disease Course, and Treatment Strategy of Crohn’s Disease Patients from the Veszprem Cohort, Western Hungary: A Population-based Inception Cohort Study Between 2007 and 2018
Lorant Gonczi, Laszlo Lakatos, Zsuzsanna Kurti, Petra A Golovics, Tunde Pandur, Gyula David, Zsuzsanna Erdelyi, Istvan Szita, Peter L Lakatos
doi : 10.1093/ecco-jcc/jjac132
Journal of Crohn's and Colitis, Volume 17, Issue 2, February 2023, Pages 240–248
The number of prospective population-based studies on Crohn’s disease[CD] is still limited from Eastern Europe. The present study is a continuation of the Veszprem IBD cohort. Our aim was to analyse incidence, prevalence, disease phenotype, treatment strategy, disease course, and surgical outcomes in a prospective population-based inception cohort including CD patients diagnosed between 2007 and 2018.
Paediatric Inflammatory Bowel Disease: A Multi-Stakeholder Perspective to Improve Development of Drugs for Children and Adolescents
Nicholas M Croft, Lissy de Ridder, Anne M Griffiths, Jeffrey S Hyams, Frank M Ruemmele, Dan Turner, Katharine Cheng, Irja Lutsar, Marco Greco, Zuzanna Gołębiewska, Floriane Laumond, Maria Cavaller-Bellaubi, Adam Elgreey, Tara A Altepeter, Chrissi Pallidis, Koen Norga, Robert Nelson, Wallace Crandall, Gilles Vassal
doi : 10.1093/ecco-jcc/jjac135
Journal of Crohn's and Colitis, Volume 17, Issue 2, February 2023, Pages 249–258
Despite recent approvals for new drugs to treat adults with Crohn’s disease or ulcerative colitis, there are only two approved advanced treatment options [infliximab and adalimumab] for children with inflammatory bowel disease [IBD].
The Incidence and Prevalence of Paediatric- and Adult-Onset Inflammatory Bowel Disease in Denmark During a 37-Year Period: A Nationwide Cohort Study (1980–2017)
Maria Dorn-Rasmussen, Bobby Lo, Mirabella Zhao, Gilaad G Kaplan, Mikkel Malham, Vibeke Wewer, Johan Burisch
doi : 10.1093/ecco-jcc/jjac138
Journal of Crohn's and Colitis, Volume 17, Issue 2, February 2023, Pages 259–268
Incidence rates of inflammatory bowel disease [IBD] reported from developed countries are rising, with some levelling out. The aim of this study was to assess the disease burden of IBD by estimating the incidence and prevalence across age groups and projecting these to 2030 in a high-incidence country.
Comparison of the Risk of Crohn’s Disease Postoperative Recurrence Between Modified Rutgeerts Score i2a and i2b Categories: An Individual Patient Data Meta-analysis
Pauline Rivière, Joel Pekow, Nassim Hammoudi, Pauline Wils, Peter De Cruz, Christina Pu Wang, MÃriam Mañosa, Jacob Ollech, Matthieu Allez, Maria Nachury, Michael A Kamm, Maya Ahanori, Marc Ferrante, Anthony Buisson, Siddarth Singh, David Laharie, Momar Diouf, Mathurin Fumery
doi : 10.1093/ecco-jcc/jjac137
Journal of Crohn's and Colitis, Volume 17, Issue 2, February 2023, Pages 269–276
The modified Rutgeerts’ score [RS] differentiates i2a—lesions confined to the anastomosis—and i2b—more than five aphthous ulcers in the neoterminal ileum with normal intervening mucosa, with or without anastomotic lesions—categories.
An Extremes of Phenotype Approach Confirms Significant Genetic Heterogeneity in Patients with Ulcerative Colitis
Sally Mortlock, Anton Lord, Grant Montgomery, Martha Zakrzewski, Lisa A Simms, Krupa Krishnaprasad, Katherine Hanigan, James D Doecke, Alissa Walsh, Ian C Lawrance, Peter A Bampton, Jane M Andrews, Gillian Mahy, Susan J Connor, Miles P Sparrow, Sally Bell, Timothy H Florin, Jakob Begun, Richard B Gearry, Graham L Radford-Smith
doi : 10.1093/ecco-jcc/jjac121
Journal of Crohn's and Colitis, Volume 17, Issue 2, February 2023, Pages 277–288
Ulcerative colitis [UC] is a major form of inflammatory bowel disease globally. Phenotypic heterogeneity is defined by several variables including age of onset and disease extent. The genetics of disease severity remains poorly understood. To further investigate this, we performed a genome wide association [GWA] study using an extremes of phenotype strategy.
GAS6 From CD200+ Adipose-Derived Stem Cells Mitigates Colonic Inflammation in a Macrophage-Dependent Manner
Zhen-Xing Liang, Hua-Shan Liu, Li Xiong, Zi-Wei Zeng, Xiao-Bin Zheng, Liang Kang, Ping Lan, Xian-Rui Wu
doi : 10.1093/ecco-jcc/jjac123
Journal of Crohn's and Colitis, Volume 17, Issue 2, February 2023, Pages 289–301
Stem cell therapy is a promising cell-based treatment modality for inflammatory bowel diseases [IBD], but its application is limited by the nature of cell heterogeneity.
Time to Endorse A Sensitive Method for Scoring Endoscopic Activity of Ulcerative Colitis in Clinical Research
Neeraj Narula, Shahin Merat, David Liu, David Pugatch, Walter Reinisch
doi : 10.1093/ecco-jcc/jjac120
Journal of Crohn's and Colitis, Volume 17, Issue 2, February 2023, Pages 302–304
The endoscopic scoring of ulcerative colitis is routinely used for both individual patient management and as an endpoint in clinical trials.
Venous Thromboembolism Following Discharge from Hospital Among Patients Admitted for Inflammatory Bowel Diseases
Cong Dai, Yu-hong Huang
doi : 10.1093/ecco-jcc/jjac125
Journal of Crohn's and Colitis, Volume 17, Issue 2, February 2023, Page 305
Venous Thromboembolism Following Discharge from Hospital in Patients Admitted for Inflammatory Bowel Diseases—Authors’ Reply
Philip R Harvey, Nigel J Trudgill
doi : 10.1093/ecco-jcc/jjac162
Journal of Crohn's and Colitis, Volume 17, Issue 2, February 2023, Page 306
Erratum to: You Are What You Eat? Growing Evidence That Diet Influences the Risk of Inflammatory Bowel Disease
doi : 10.1093/ecco-jcc/jjac131
Journal of Crohn's and Colitis, Volume 17, Issue 2, February 2023, Page 307
